A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome

NCT01641224 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2014-05-12

No results posted yet for this study

Summary

The purpose of this study is to test the efficacy and safety of pinaverium and an herbal medication for irritable bowel syndrome (IBS). Pinaverium has been in many countries, but there is no randomized, double-blind, large sample size, and placebo-controlled study on this medication yet. Tong Xie Yao Fang (Formula for pain and diarrhea) is a historically and contemporarily used traditional Chinese medicine that can be used for IBS. The hypothesis is that the two remedies are effective and safe for IBS treatment when tested by modern clinical standards and criteria.

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

Pinaverium

To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.

DEVICE

Atractylodes

Atractylodes (\~10-15g)

DEVICE

Paeonia Lactiflora

Paeonia Lactiflora (\~15-30g)

DEVICE

Tangerine Peel

Tangerine Peel (\~10g)

DRUG

Ledebouriella Root

Ledebouriella Root (\~10g)

DRUG

Radix codonopsitis

Radix codonopsitis (\~10-15g)

DRUG

Radix curcumae

Radix curcumae (\~10g)

DRUG

Fingered citron

Fingered citron (\~10g)

DRUG

Tuckahoe

Tuckahoe (15g)

DRUG

Placebo

Placebo is blindly given to patients.

Sponsors & Collaborators

Principal Investigators

  • Jun Xiao, Ph.D. · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-05-31
Completion
2014-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01641224 on ClinicalTrials.gov